True Wealth Design’s Standard BioTools LAB Stock Holding History

True Wealth Design’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-354	Closed	-$292	–	2692
2026 Q2	$292	Sell	354 -1,220	-78%	-$1.15K	﹤0.01%	2363
2026 Q1	$1.45K	Sell	1,574 -371	-19%	-$449	﹤0.01%	1671
2025 Q4	$2.49K	Sell	1,945 -341	-15%	-$458	﹤0.01%	1369
2025 Q3	$2.97K	Hold	2,286	–	–	﹤0.01%	1312
2025 Q2	$2.74K	Buy	2,286 +1,190	+109%	+$1.32K	﹤0.01%	1043
2025 Q1	$1.18K	Buy	+1,096	New	+$1.54K	﹤0.01%	1206

Other funds holding LAB

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

True Wealth Design's LAB Position: Q3 2026 in Review

True Wealth Design sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 354 shares — an estimated $292 sold.

True Wealth Design first reported a position in LAB in Q1 2025 and held it in 6 quarters. The position peaked at $2.97K in Q3 2025. 3 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

True Wealth Design reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
True Wealth Design sold 354 Standard BioTools shares in Q3 2026, an estimated $292.
True Wealth Design first reported a position in Standard BioTools in Q1 2025 and held it in 6 quarters.
True Wealth Design's Standard BioTools position peaked at $2.97K in Q3 2025.
3 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.